FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Scythian Biosciences

  • Home
  •  | 
  • Tag Archives: "Scythian Biosciences"

Verano™ Holdings Launched to Consolidate National Cannabis Assets with $120 Million Financing and Acquisition of Florida Licenses

Verano™ Holdings Launched to Consolidate National Cannabis Assets with $120 Million Financing and Acquisition of Florida Licenses
Verano Holdings, LLC Co-founders George Archos and Sam Dorf today announced an $120million financing comprised of $88 million equity investment by Toronto-based Scythian Biosciences Corp. (TSXV:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF), an additional private financing of $32 million, as well as acquisitions, transactions and executive hires that bring together numerous successful cannabis enterprises under the newly created Verano Holdings, LLC, and verano™ master brand. Headquartered in Chicago, Verano Holdings launches as one of the United States’ preeminent, privately owned, vertically integrated cannabis companies with an aggressive expansion strategy underway to become one of the largest and most profitable cannabis companies in the U.S. in 2019.
Read more

Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis

Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) applauds the United Kingdom’s decision to allow specialist doctors the option to legally issue prescriptions for cannabis-based medicines when they believe patients could benefit from the treatment. Specialist doctors in England, Wales and Scotland will be able to prescribe cannabis-derived medicines in less than a month.
Read more

Scythian Biosciences Appoints Brady Cobb as CEO

Scythian Biosciences Appoints Brady Cobb as CEO
TORONTO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) announced today Brady Cobb, a leading voice in the medical cannabis industry, has been appointed Chief Executive Officer. Effective October 3, 2018, Mr. Cobb replaces Rob Reid, who has stepped down to focus on European Cannabis Investment opportunities and will remain as an active member of the Board of Directors and key person in driving the company’s strategic direction.
Read more

Scythian Biosciences Announces Intention to Commence Normal Course Issuer Bid to Repurchase up to 5% of its Common Shares

Scythian Biosciences Announces Intention to Commence Normal Course Issuer Bid to Repurchase up to 5% of its Common Shares
TORONTO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (“Scythian” or the “Company”) (CSE:SCYB) (Frankfurt: 9SB) (OTC – Nasdaq Intl: SCCYF) announced its intention to commence a normal course issuer bid (“NCIB”), under which the Company may purchase up to 2,451,861 of the Company’s common shares, representing approximately 5% of its issued and outstanding common shares (the “Shares”). The Company is commencing the NCIB because it believes that, from time to time, the market price of its Shares may not fully reflect the underlying value of the Company’s business and future prospects. Scythian believes that, at such times, the repurchase of its Shares for cancellation represents an appropriate use of the Company’s financial resources and will enhance shareholder value.
Read more